Methadone or buprenorphine should be considered as standard first-line treatment for opioid use disorder, with slow-release oral morphine as a second-line treatment option.
Of the 12,203 drugs in the pipeline, 5,319 were in Phase 1 while 4,979 were in Phase 2. In addition, there were 1,671 Phase 3 drugs and 234 in the pre-registration stage.